Ketanest S

Esketamine, the active ingredient in Ketanest S, is an NMDA receptor antagonist presented as a sterile solution for intramuscular and intravenous use. It provides dissociative anesthesia and analgesia for patients undergoing surgical procedures.

GNH USA supplies Ketanest S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All batches are manufactured under GMP conditions and are fully traceable from source to end‑user, ensuring patient safety and therapeutic consistency.

Esketamine is an NMDA receptor antagonist used in anesthesia and analgesia pathways.

- Induction of anesthesia: produces rapid, controllable loss of consciousness for surgical procedures. - Analgesia: provides potent pain relief during and after operative interventions. - Procedural sedation: offers quick onset sedation for short, minimally invasive procedures.

Esketamine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Nausea: mild to moderate upset stomach. - Increased blood pressure: temporary elevation during induction. - Vivid dreams or hallucinations: sensory disturbances during recovery. - Dissociation: sense of detachment from environment. - Headache: mild to moderate pain.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort requiring support. - Severe hypertension: marked rise in blood pressure needing intervention. - Emergence delirium: confusion or agitation upon waking. - Seizures: rare convulsive episodes. - Cardiac arrhythmias: irregular heart rhythms. - Allergic reactions: rash, itching, or anaphylaxis.

When using Ketanest S, clinicians should observe specific safety measures.

- Patient assessment: evaluate cardiovascular and neurological status before administration. - Cardiovascular monitoring: continuously monitor blood pressure and heart rate. - Respiratory monitoring: ensure adequate ventilation and oxygenation throughout the procedure. - Contraindications: avoid in patients with elevated intracranial pressure or severe hepatic impairment. - Drug interaction vigilance: review concomitant medications that may potentiate CNS effects. - Use in elderly: start with lower doses and monitor closely for hemodynamic changes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Esketamine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents: may cause excessive hypertension. - CNS depressants (e.g., benzodiazepines): can deepen sedation beyond intended levels. - Drugs increasing intracranial pressure: may exacerbate cerebral edema.

Moderate Interactions (Monitor Closely): - Opioids: additive analgesic effect may increase respiratory depression risk. - Other anesthetic agents: may require dose adjustments to avoid over‑sedation. - Antihypertensives: monitor blood pressure for potential instability. - Anticholinergic drugs: may influence heart rate variability.